BIOMEA FUSION (BMEA)
(Delayed Data from NSDQ)
$2.08 USD
+0.12 (6.12%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $2.08 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth C Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Biomea Fusion, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
BMEA 2.08 +0.12(6.12%)
Will BMEA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BMEA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMEA
Biomea Fusion (BMEA) Upgraded to Buy: Here's What You Should Know
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
BMEA: What are Zacks experts saying now?
Zacks Private Portfolio Services
After Plunging -19.32% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
After Plunging -20.42% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
BMEA Stock Up 9% as FDA Lifts Clinical Hold on 2 Diabetes Studies
Other News for BMEA
BMEA forms Bearish Engulfing on September 17
Is BMEA primed for upward momentum? Pocket Pivot shows up after advancing 3.06%
Biomea Fusion: Promising Clinical Pipeline and Strategic Focus Drive Buy Rating
BMEA forms 20 Day Moving Average Support on September 15
Biomea Fusion (BMEA) Unveils Promising Diabetes Therapy Data